#South Korea #Seoul #Sky Labs #CART BP pro #hypertension device

Sky Labs' CART BP Pro: A Game Changer in Hypertension Management

Sky Labs, led by CEO Jack ByungHwan Lee, is stepping into the global spotlight with its innovative product, the CART BP pro. Recently unveiled during exclusive symposiums at the 35th European Society of Hypertension Congress in Gdańsk, Poland, and the British Cardiovascular Society Annual Conference in Manchester, this device is set to redefine how hypertension is monitored and managed worldwide.

A New Era in Blood Pressure Monitoring

This revolutionary device is stirring conversations in the medical community, particularly as it aligns with the latest recommendations from the Korean Society of Hypertension (KSH), which have integrated cuff-less, validated devices as feasible options for blood pressure monitoring outside clinical environments. South Korea is positioning itself as a leader in the practical application of such technologies, and CART BP pro is at the forefront of this movement.

In comparative studies against traditional measurement techniques, the CART BP pro has met the rigorous international standards set by ISO 81060-2:2018. The device not only adheres to these standards but also fulfills the demanding criteria established by the European Society of Hypertension for cuff-less devices. This includes extensive testing on static trials, positioning tests, and performance during waking and sleeping hours.

Rapid Adoption in Healthcare Settings

Since its introduction, the CART BP pro has gained traction in hospitals and clinics throughout South Korea, with over 260,000 prescriptions issued as of May 2026. Such widespread adoption underscores the device's potential to ease patient care and improve health outcomes. The global healthcare community's response has been overwhelmingly positive, as experts highlight South Korea's progressive healthcare system that enables quick integration of innovative solutions like the CART BP pro.

Professor George Stergiou, president of the International Society of Hypertension, expressed optimism about South Korea's endeavors, commending the thorough evaluation of both the capabilities and limitations of cuff-less devices. He pointed out that if the CART BP pro can demonstrate enhanced treatment adherence and blood pressure control, it would provide significant clinical evidence that benefits health management practices worldwide.

Carmel McEniery from the University of Cambridge praised South Korea for its forward-looking healthcare environment, while Professor Philip Lewis emphasized that overcoming the limitations of traditional methods allows for the collection of comprehensive blood pressure data, thereby maximizing the potential for managing hypertension and enhancing clinical practices.

Achievements and Future Expansion

Sky Labs has garnered significant regulatory milestones, including CE-MDR certification and subsequent registration with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in early 2026. These achievements are crucial for accelerating the device's expansion into European markets, including the UK, reinforcing Sky Labs' position as a leader in digital health technologies.

The future seems bright for Sky Labs and its innovative CART BP pro as it paves the way for a new era in hypertension management that prioritizes patient comfort and clinical efficacy.

About Sky Labs

Founded in September 2015, Sky Labs specializes in health technology, particularly developing and operating the CART medical device, which is designed for continuous monitoring of patients with chronic illnesses. The CART BP pro is their flagship product, developed for 24-hour blood pressure measurement. By 2024, it received recognition from the Health Insurance Review and Assessment Service (HIRA) and was approved for outpatient monitoring. The company continues to innovate and expand its product offerings, maintaining its dedication to improving patient care globally.